Contract 75A50324F80012
Biocryst Pharmaceuticals Inc · Department Of Health And Human Services · September 23, 2024
Biocryst Pharmaceuticals Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 23, 2024 for $13.88 million of work in pharmaceutical preparation manufacturing. Performance is in Durham, NC. This is a task or delivery order issued under parent IDIQ 36F79721D0166. The contract has been modified 1 time since the base award It uses firm fixed-price contract pricing. The most recent modification was on March 27, 2026. If all options are exercised, the contract could reach $69.39 million.
Contract details
- PIID
- 75A50324F80012
- Parent IDIQ
- 36F79721D0166
- Award type
- Delivery Order
- Pricing
- Firm Fixed Price
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Durham, NC
- First action
- September 23, 2024
- Latest action
- March 27, 2026
Description
EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI MODIFICATION TO ADJUST END DATE DUE TO OPTIONS NOT EXERCISED.
Modification timeline
-
March 27, 2026Mod P00002 · Other Administrative Action$13.88M
-
September 23, 2024Base awardPERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN))$13.88M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Four Points Technology, L.L.C. | Department Of Health And Human Services | March 31, 2026 | $246.6K |
| Astrazeneca Pharmaceuticals Lp | Department Of Health And Human Services | March 31, 2026 | $122.8K |
| Emergent Biosolutions Canada Inc | Department Of Health And Human Services | March 30, 2026 | $256.40M |
| Ase Direct, Inc. | Department Of Health And Human Services | March 30, 2026 | $49.0K |
| Mckesson Corporation | Department Of Health And Human Services | March 30, 2026 | $9.00M |
| Pfizer Inc | Department Of Health And Human Services | March 27, 2026 | $187.56M |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50324F80012?
Contract 75A50324F80012 is a federal contract awarded to Biocryst Pharmaceuticals Inc by Department Of Health And Human Services on September 23, 2024 for $13.88 million of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 1 time since the base award.
Who won contract 75A50324F80012?
Biocryst Pharmaceuticals Inc won contract 75A50324F80012 from Department Of Health And Human Services.
How much is contract 75A50324F80012 worth?
Contract 75A50324F80012 has obligated $13.88 million to date, with a total potential value of $69.39 million if all options are exercised.